Global multiple sclerosis treatment market has been witnessing fast strides with various new drugs in late stage pipeline. Recently, Novartis approved FDA approval for Mayzent, the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS). The drug is expected to address critical unmet need of multiple sclerosis patients belonging to varied disease categories.
The report ?Global Multiple Sclerosis Therapeutics Market (By Region - North America (The US), Europe & Asia Pacific) Outlook 2025? provides an in-depth analysis of global multiple sclerosis market with focus on major markets in regions such as North America, Europe & Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global multiple sclerosis market. The report has been segmented as following:-
Geographical Coverage
? North America - The US
? Europe
? Asia Pacific
Key Vendors
? Biogen Inc.
? Teva Pharmaceuticals
? Bayer AG
? Sanofi Genzyme
? Novartis AG
? Pfizer Inc.


Multiple sclerosis is a chronic, inflammatory, autoimmune disease that impacts the central nervous system. It is one of the world?s most common neurologic disorders and leading cause of non-traumatic neurologic disability in young adults. The disease damages myelin, the substance which surrounds and insulates our nerve cells, disrupting communication in the nervous system. This leads to development of wide range of ailments including physical, mental, and sometimes psychiatric problems. Multiple sclerosis is incurable disease with treatment paradigm primarily focusing on slowing down disease progression by managing its symptoms. Moreover, the course of the disease can also be altered by a range of disease-modifying therapies (DMTs).
Growth of global multiple sclerosis therapeutics market is attributed to increasing prevalence of multiple sclerosis worldwide. The disease currently affects around 2.5 million people worldwide. Out of these, nearly 1 million people are affected by MS in the US alone. Other factors such as ageing population, robust drug pipeline, rising healthcare expenditure, etc. are also major growth drivers of the market. However, the market faces several challenges due to patent expiration of major drugs, stringent regulatory norms, high cost of drugs and side-effects associated with extended use of various multiple sclerosis drugs.
The report ? ? provides information on the current scenario, detailed market outlook of the global multiple sclerosis market, with regional analysis done across markets in North America, Europe and Asia Pacific region. The US is the world?s largest market for multiple sclerosis therapeutics due to technological advancements in multiple sclerosis treatments in the nation. Future forecasts of the market overall and across various regions till 2025 is provided in the report. Furthermore, major industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.
Major international industry players operating in the global multiple sclerosis therapeutics market include Biogen Inc., Teva Pharmaceuticals, Bayer AG, Sanofi Genzyme, Novartis AG, Pfizer Inc., among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global multiple sclerosis therapeutics market.
?